CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalEuropean Journal of Cancer
Volume97
DOIs
Publication statusPublished - Jul 2018

Keywords

  • Biomarkers, Tumor/genetics
  • CTLA-4 Antigen/genetics
  • Endocrine System Diseases/chemically induced
  • Humans
  • Ipilimumab/adverse effects
  • Melanoma/drug therapy
  • Polymorphism, Genetic
  • Prognosis
  • Skin Neoplasms/drug therapy

Cite this